NASDAQ:ETNB 89bio (ETNB) Stock Forecast, Price & News $20.30 +0.13 (+0.64%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$19.97▼$20.4950-Day Range$14.15▼$20.4552-Week Range$2.91▼$20.85Volume693,763 shsAverage Volume1.12 million shsMarket Capitalization$1.48 billionP/E RatioN/ADividend YieldN/APrice Target$34.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media 89bio MarketRank™ ForecastAnalyst RatingBuy3.14 Rating ScoreUpside/Downside67.5% Upside$34.00 Price TargetShort InterestHealthy9.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.15Based on 10 Articles This WeekInsider TradingAcquiring Shares$41.02 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.92) to ($2.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector421st out of 987 stocksPharmaceutical Preparations Industry197th out of 482 stocks 3.6 Analyst's Opinion Consensus Rating89bio has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.00, 89bio has a forecasted upside of 67.5% from its current price of $20.30.Amount of Analyst Coverage89bio has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.91% of the outstanding shares of 89bio have been sold short.Short Interest Ratio / Days to Cover89bio has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 89bio has recently decreased by 4.37%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend Yield89bio does not currently pay a dividend.Dividend Growth89bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETNB. Previous Next 1.7 News and Social Media Coverage News Sentiment89bio has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for 89bio this week, compared to 3 articles on an average week.Search InterestOnly 21 people have searched for ETNB on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added 89bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 89bio insiders have bought 3,592.96% more of their company's stock than they have sold. Specifically, they have bought $41,016,456.00 in company stock and sold $1,110,666.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of 89bio is held by insiders.Percentage Held by Institutions87.78% of the stock of 89bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 89bio are expected to decrease in the coming year, from ($1.92) to ($2.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 89bio is -7.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 89bio is -7.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio89bio has a P/B Ratio of 6.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 89bio (NASDAQ:ETNB) Stock89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.Read More Receive ETNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ETNB Stock News HeadlinesJune 8, 2023 | americanbankingnews.com89bio, Inc. (NASDAQ:ETNB) CEO Rohan Palekar Sells 15,000 Shares of StockJune 8, 2023 | americanbankingnews.com89bio, Inc. (NASDAQ:ETNB) Director Sells $111,937.50 in StockJune 10, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>June 7, 2023 | finance.yahoo.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 7, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on 89bio (ETNB)June 7, 2023 | finance.yahoo.com89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023June 4, 2023 | fool.com89bio (NASDAQ: ETNB)June 2, 2023 | americanbankingnews.com89bio (NASDAQ:ETNB) Stock Price Up 3.3%June 10, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 29, 2023 | finance.yahoo.com89BIO (ETNB) Just Overtook the 20-Day Moving AverageMay 28, 2023 | seekingalpha.com89bio: Great Prospects After Excellent Phase 2 DataMay 23, 2023 | finance.yahoo.com89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)May 18, 2023 | seekingalpha.com89bio (ETNB) Investor Presentation - SlideshowMay 17, 2023 | americanbankingnews.com89bio (NASDAQ:ETNB) Reaches New 12-Month High at $18.88May 15, 2023 | americanbankingnews.com89bio, Inc. (NASDAQ:ETNB) Receives $32.33 Consensus Target Price from BrokeragesMay 14, 2023 | americanbankingnews.com89bio, Inc. (NASDAQ:ETNB) Insider Sells $247,799.13 in StockMay 13, 2023 | finance.yahoo.comInstitutional investors are 89bio, Inc.'s (NASDAQ:ETNB) biggest bettors and were rewarded after last week's US$90m market cap gainMay 11, 2023 | msn.comOppenheimer Reiterates 89bio (ETNB) Outperform RecommendationMay 10, 2023 | msn.comHC Wainwright & Co. Maintains 89bio (ETNB) Buy RecommendationMay 10, 2023 | americanbankingnews.com89bio, Inc. to Post Q2 2023 Earnings of ($0.43) Per Share, HC Wainwright Forecasts (NASDAQ:ETNB)May 9, 2023 | americanbankingnews.comHC Wainwright Increases 89bio (NASDAQ:ETNB) Price Target to $35.00May 8, 2023 | americanbankingnews.comCantor Fitzgerald Boosts 89bio (NASDAQ:ETNB) Price Target to $41.00May 5, 2023 | finance.yahoo.comWall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should KnowApril 22, 2023 | americanbankingnews.com89bio (NASDAQ:ETNB) Stock Price Down 6.1%April 20, 2023 | americanbankingnews.comBrokerages Set 89bio, Inc. (NASDAQ:ETNB) Price Target at $32.22April 19, 2023 | americanbankingnews.comShort Interest in 89bio, Inc. (NASDAQ:ETNB) Increases By 44.0%April 13, 2023 | finance.yahoo.comWall Street Analysts See a 79.36% Upside in 89BIO (ETNB): Can the Stock Really Move This High?See More Headlines ETNB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETNB Company Calendar Last Earnings5/04/2023Today6/10/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ETNB CUSIPN/A CIK1785173 Webwww.89bio.com Phone415-432-9270FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Forecast$34.00 High Stock Price Forecast$50.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+67.5%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.72% Return on Assets-40.53% Debt Debt-to-Equity Ratio0.05 Current Ratio20.56 Quick Ratio20.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book6.77Miscellaneous Outstanding Shares72,870,000Free Float69,662,000Market Cap$1.48 billion OptionableNot Optionable Beta0.76 Key ExecutivesMr. Rohan Palekar (Age 56)CEO & Director Comp: $829.41kMr. Quoc Le-Nguyen (Age 54)Chief Technical Operations Officer & Head of Quality Comp: $571.12kDr. Harry Mansbach M.D. (Age 57)Chief Medical Officer Comp: $603.22kMr. Ryan Stephen Martins (Age 44)Chief Financial Officer Mr. Shiva K. Natarajan (Age 56)Sr. VP of Fin. & Principal Accounting Officer Ms. Melissa AbelSr. VP of Commercial Strategy & CommunicationsMs. Amanda HillVP of People & CultureMs. Yun BaiVP & Head of CMCMr. Paul ShinSr. VP of R&D OperationsMore ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXAgios PharmaceuticalsNASDAQ:AGIOAurinia PharmaceuticalsNASDAQ:AUPHSyndax PharmaceuticalsNASDAQ:SNDXZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsRohan PalekarSold 15,000 sharesTotal: $300,000.00 ($20.00/share)Edward Morrow Atkinson IIISold 6,250 sharesTotal: $111,937.50 ($17.91/share)Ameriprise Financial Inc.Bought 251,984 shares on 5/22/2023Ownership: 0.346%JPMorgan Chase & Co.Bought 16,000 shares on 5/18/2023Ownership: 0.000%Gilder Gagnon Howe & Co. LLCBought 26,126 shares on 5/16/2023Ownership: 0.104%View All Insider TransactionsView All Institutional Transactions ETNB Stock - Frequently Asked Questions Should I buy or sell 89bio stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ETNB shares. View ETNB analyst ratings or view top-rated stocks. What is 89bio's stock price forecast for 2023? 7 brokerages have issued 12-month price objectives for 89bio's shares. Their ETNB share price forecasts range from $24.00 to $50.00. On average, they expect the company's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 67.5% from the stock's current price. View analysts price targets for ETNB or view top-rated stocks among Wall Street analysts. How have ETNB shares performed in 2023? 89bio's stock was trading at $12.73 at the beginning of 2023. Since then, ETNB shares have increased by 59.5% and is now trading at $20.30. View the best growth stocks for 2023 here. When is 89bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ETNB earnings forecast. How were 89bio's earnings last quarter? 89bio, Inc. (NASDAQ:ETNB) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.02. What ETFs hold 89bio's stock? ETFs with the largest weight of 89bio (NASDAQ:ETNB) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), SPDR S&P Biotech ETF (XBI), Invesco Raymond James SB-1 Equity ETF (RYJ), Harbor Health Care ETF (MEDI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of 89bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO). When did 89bio IPO? (ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. What is 89bio's stock symbol? 89bio trades on the NASDAQ under the ticker symbol "ETNB." Who are 89bio's major shareholders? 89bio's stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (4.21%), Federated Hermes Inc. (3.49%), Suvretta Capital Management LLC (3.03%), Boxer Capital LLC (2.88%), BVF Inc. IL (2.53%) and BlackRock Inc. (1.71%). Insiders that own company stock include Edward Morrow Atkinson III, Gregory Grunberg, Longitude Capital Partners Iii, Michael R Hayden, Ollin B Sykes, Orbimed Advisors Llc, Quoc Le-Nguyen, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins. View institutional ownership trends. How do I buy shares of 89bio? Shares of ETNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 89bio's stock price today? One share of ETNB stock can currently be purchased for approximately $20.30. How much money does 89bio make? 89bio (NASDAQ:ETNB) has a market capitalization of $1.48 billion. The company earns $-102,030,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. How can I contact 89bio? 89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for the company is www.89bio.com. The company can be reached via phone at 415-432-9270 or via email at investors@89bio.com. This page (NASDAQ:ETNB) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.